ABT-493: Additional Phase IIb data

Additional data from 34 treatment-naive or pegylated interferon treatment-experienced, non-cirrhotic patients with HCV genotype 1 infection in the open-label, international Phase IIb SURVEYOR-I trial showed that once-daily oral 300 mg ABT-493 plus 120 mg ABT-530 for 8 weeks led to an SVR 12 weeks after the end of treatment in 97% of patients. In 40 treatment-naive or pegylated interferon null responsive, non-cirrhotic patients with HCV genotype 1 infection, once-daily 200 mg ABT-493 plus 120 mg ABT-530 for 12 weeks led to an SVR12 rate of 100%. In 39 treatment-naive or pegylated interferon null responsive, non-cirrhotic patients with HCV genotype 1 infection, once-daily 200 mg ABT-493 plus 40 mg ABT-530 for 12 weeks led to an SVR12 rate of 97%. Data were presented at the American Association for the Study of Liver Diseases meeting in San Francisco. ...